A study in healthy people to see how zongertinib is taken up into the blood when given as tablets made by two different manufacturers

2023-510495-31-00 Protocol 1479-0019 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 24 Apr 2024 · End 15 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1479-0019

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 56
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
24 Apr 2024 → 15 Jul 2024
Decision date (initial)
2024-04-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-510495-31-00
WHO UTN
U1111-1303-4345

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 56 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
CRS Clinical Research Services Management GmbH
NA, Grenadierstrasse 1, Neckarstadt, Mannheim

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-04-24 2024-07-15 2024-04-30 2024-05-15

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-15 Germany Acceptable
2024-04-05
2024-04-05
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-19 Germany Acceptable
2024-07-09
2024-07-09